5 Reasons Why GlaxoSmithKline Shareholders Should Be Excited About the Future
While presenting at the J.P. Morgan Healthcare Conference on Tuesday, CEO Andrew Witty hit on five key points that should get investors excited about GlaxoSmithKline's long-term potential.
Mylan N.V. Fires a Shot at GlaxoSmithKline
A generic version of Advair Diskus could be coming to the United States.
Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015
Clinical progress doesn't always translate into a higher share price.